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A recent UK government inquiry, the Women
and Equalities Committee investigation into
women in senior positions, questioned why
there are so few women at the top. The
committee chair, Maria Miller, commented:
Women get the best degrees from the best
universities and have done for almost two decades.
Despite already making up half of graduate
intake in many major companies only a handful
of women get through to be appointed to the top
executive director positions (Women and
Equalities Committee website, 6 April 2017).
This article reports on the findings from a
recent study of women on the boards of directors
of National Health Service (NHS) foundation
trusts (FTs) in England (Ellwood and Garcia-
Lacalle, 2015) in the context of the government
inquiry and progress since the Davies Review
in 2010.
The Davies Review
In August 2010, Lord Davies was tasked by the
government to lead a review into how obstacles
can be removed to allow more women to reach
board level positions. Following a wide
consultation, Lord Davies published his
recommendations in February 2011. The
review recommended that UK-listed companies
in the FTSE 100 should be aiming for a
minimum of 25% female board member
representation by 2015. It also recommended
that FTSE 350 companies should be setting
their own challenging targets. Lord Davies
called on chairpersons to announce these goals
within six months of his report (Davies, 2011).
The 5 Year Summary reported on progress
(Davies, 2015):
There are more women on FTSE 350 boards
than ever before, with the representation of women
more than doubling since 2011—now at 26.1%
on FTSE 100 boards and 19.6% on FTSE 250
boards. We have also seen a dramatic reduction
in the number of all-male boards. There were
152 in 2011. Today there are no all-male boards
in the FTSE 100 and only 15 in the FTSE 250.
The progress on the Davies Review is set
out in table 1. In the 5 Year Summary of the
review, in October 2015, a five-step approach
was proposed: a voluntary approach; with a
target of 33% for female representation with
more chairs to cover all listed companies; a
focus on the executive layer; steered by an
independent body with momentum
maintained. In February 2016, the Department
for Business, Innovation & Skills announced
that Sir Philip Hampton, chair of
GlaxoSmithKline, would lead an independent
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in the executive level of FTSE 350 companies.
Dame Helen Alexander would be the deputy
chair of the review. The Hampton–Alexander
Review considered the voluntary business-led
approach to be working and no need for quotas,
despite legislative quotas being a common
approach in leading European and Scandinavian
countries: Norway, France, Finland, Belgium,
The Netherlands and, most recently, Germany.
Women on boards and research studies
Boards hire and fire the chief executive and are
responsible for ensuring value creation:
shareholder value in FTSE companies and public
value when running public sector organizations.
Board effectiveness is enhanced by independence
(as promoted by the Cadbury Report, 1992) and
this is improved by gender diversity. Several
studies from management consultancy firms
suggest improvements stem from using the whole
talent pool and gaining diverse perspectives;
boards would be more responsive to customers
and stakeholders (Catalyst, 2007; McKinsey,
2007; Credit Suisse, 2012). It is evident from
many countries’ boardroom gender policies that
policy-makers see female presence on boards as
important, but how these female ‘superheroes’
perform is difficult to determine (Adams, 2015).
Published work frequently has data limitations
and lacks causal inferences. For example,
performance can causally affect board diversity
if women choose to join boards of better-
performing firms or if better-performing firms
choose to have more female directors. In what
areas do women influence board performance?
Will the ways in which female directors are
different from male directors change over time
and as presence increases?
There have been few research studies
undertaken where women have a substantial
presence on boards of directors and fewer still
where women are in the most senior positions
(see table 2).
The research study of boards of directors in
NHS FTs
We examined the influence of presence and
position of women on the boards of directors of
NHS FTs. NHS FTs provide a context where
there is substantial female presence and where
women frequently occupy one of the most
senior positions. NHS FTs provide healthcare
services, and were set up to have greater
freedom from government to decide their
strategy and the way health services are run.
FTs have a board of directors (executives and
non-executives) and operate according to a
corporate governance code (Ellwood and
Garcia-Lacalle, 2016). However, unlike most
corporate boards where there is only one or a
small minority of women, one third of voting
members of NHS boards are women and one
third are chaired by a woman. More specifically,
during our three-year study period*:
•All FTs have a female board member and, on
average, over a third (36%) of directors are
female. While there are no all-male boards
in the FTSE 100, there are 15 in the FTSE
250; and 45% of FTSE 100 companies and
61% of FTSE 350 companies have not
reached the 25% target for women board
members.
•In FTs, female presence is higher for executive
directorships (40%) than for non-executives
(32%). In the FTSE 100, less than 10% of
executive directors are women and 31.4%
of non-executive directors are women.
•In FTs, females occupy 29% of the chair
positions and 36% of the chief executive
seats. In the FTSE 100, there are three
women in chair positions and five chief
executives.
FTs are accountable to local communities
through members and governors, parliament
and to Monitor (the regulator of FTs; now ‘NHS
Improvement’). NHS boards are running
organizations where social performance is
paramount. Academic literature supports that
female presence on boards affects firm’s corporate
social performance (Manner, 2010; Hafsi and
Turgut, 2013), but these studies are undertaken
within a context where women on boards and in
senior positions is low (table 2) . In public sector
organizations, the presence of women is more
substantial; it is also argued that social orientation
and community representation are important
therefore female presence on boards is necessary
(Ibrahim and Angelidis, 1994; Boulouta, 2013).
Table 1. Women on boards of FTSE 100 companies.
February 2011 October 2015
Women on boards 135 (12.5%) 286 (26.1%)
Women non-executive directors (NEDs) 117 (15.6%) 260 (31.4%)
Women executive directors 18 (5.5%) 26 (9.6%)
Number of women chairmen 2 3
Number of women chief executives 5 5
Total directorships 1,076 1,097
Source: Davies (2015).
*The figures for FTs relate to the average in the
study period 2008/09 to 2010/11 (Ellwood and Garcia
Lacalle, 2015), but the figures for FTSE companies
are from the Women on Boards: 5 Year Summary
(Davies, 2015), which shows a considerable
improvement over the 2011 position.
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Our principal research questions were:
•How do high levels of gender diversity on boards of
directors affect organizational performance when
social performance is paramount?
•How does the position of women (chair or chief
executive) on the boards of directors affect
organizational performance when social performance
is paramount?
We looked for support for the business
case and gender beliefs and behaviour: caring
and concern for others (Eagly, 1987), and
moral and ethical issues (Ibrahim et al., 2009).
In public service providers, such as NHS FTs,
responsiveness to stakeholders and stewardship
is important. NHS FTs also provide an excellent
case to examine the upper echelon theory put
forward by Hambrick and Mason (1984).
Under upper echelon theory a firm’s strategic
choices reflect top management, i.e. position
and not merely presence is important. NHS FTs
provide a rare opportunity to examine the
influence of women in the most senior positions
on boards of directors; earlier studies lack both
the perspective of substantial female presence
and women in the most senior positions.
Our principal research questions were
broken down into four supporting questions:
On gender diversity
•Do differences in female presence on boards
affect financial performance when women
are substantially present on boards?
•Do differences in female presence on boards
affect social performance when women are
substantially present on boards?
On women in senior positions
•Does the presence of women in the uppermost
organizational positions (chair and/or chief
executive) of the board influence financial
performance?
•Does the presence of women in the uppermost
organizational positions (chair and/or chief
executive) of the board influence social
performance?
We used return on assets to measure financial
performance. FTs are required to make a
minimum real return on assets of 3.5%, which
is paid as a dividend to the Department of
Health, which holds the public dividend capital
of NHS FTs. Return on assets is published in
the annual reports of NHS FTs:
Return on assets: operating surplus divided by total
assets less current liabilities.
We used clinical negligence costs as a proxy for
Table 2. Empirical studies of gender diversity on boards.
Country Study Gender diversity
Bliss and Potter (2002) 11% female managers
Carter et al. (2003) Mean 1.09 women on boards
9.6% female directors
Farrell and Hersch (2005) Mean 1 woman on boards
8.6% female directors
Adams and Ferreira (2009) 8.5% female directors
39% of firms with no female director
USA Bear et al. (2010) 9.6% female directors
Carter et al. (2010) Mean 1.3 women on boards
11.6% female directors
Manner (2010) 3% female CEOs
Jurkus et al. (2011) 11.7% female directors
Gul et al. (2011) Mean 1 woman on boards
9.4% female directors
35% of firms with no female director
1.7% female CEOs
1.3% female Chairs
Hafsi and Turgut (2013) 15% female directors
Canada Francoeur et al. (2008) 7% female directors
Spain Campbell and Minguez-Vera (2008) 3.2% female directors
76.3% of firms with no female directors
Norway Huse et al. (2009) 30% female directors
Torchia et al. (2011) During legislation Mean 1.5 women on boards
period requiring movement to 40% 26% of boards with no female director
female directors 19% of boards with 3 or more women




Clinical negligence costs: the higher the costs, the
higher the patients claims because of medical mistakes
or failures.
We used the data for NHS FTs in England
for the three years to 31 March 2011 and
multivariate regression techniques.
In our regression models, we included
board- and organization-related characteristics
that influenced the performance of
organizations according to the academic
literature. We included board size and board
independence. BDsize captures the number of
members of the board, including the chair.
BDindependence measures the independence
of the board as the proportion of non-executive
directors of the board over the total number of
members, excluding the chair. In addition to
board characteristics, we included control
variables related to FT characteristics, namely:
size, leverage and complexity, which are
generally accepted as affecting organizational
and board performance. The size of the FT
was represented using the natural logarithm
of assets employed, measured as total assets
less current liabilities. Leverage (the debt ratio)
was measured as the long-term debt/total assets
ratio. Complexity was measured using a
dummy variable, Nomental, which takes value
‘1’ when the FT is an acute or specialist hospital
and ‘0’ when the FT is a mental health hospital.
We are interested in the effect of gender on
both financial performance and service quality.
Therefore, we used two multivariate
regressions to test the influence of gender
diversity on FTs’ performance. We kept the
same independent and control variables for
the two regressions and only the dependent
variable, that captures one of the performance
dimensions analysed (financial performance
and service quality performance), varied. The
regression model is expressed as follows:
PERFORMANCEit = θ0 + θ1 SIZEit + θ2
LEVERAGEit+ θ3 NOMENTALit + θ4
BDSIZEit + 5 BDINDEPENDENCEit+ θ6
FEDit+ θ7 FNEDit + θ8 FCHit + θ9 FCEit + θ10
YEARit
The characteristics of the variables used in the
study are set out in table 3.
The findings
The results of the two regression models are
shown in table 4. For the financial performance
(ROA ratio), none of the independent variables
that capture female presence are significant.
Therefore, from our results, the only possible
assertion is that different female presence on
FT boards does not significantly affect financial
performance. We conjecture that, given that
most boards have high female presence,
variations in the number of women on a board
does not significantly affect financial
performance across FTs.
Our results for the service quality
performance (clinical negligence costs) show
that female presence on boards does matter,
but it is the position held by a woman and not
the proportion of women that matters. The
proportion of female executive and non-
executive directors does not significantly affect
clinical negligence costs, but female presence
in the two most influential board posts, chair
and chief executive, does make a difference.
The variable that captures that a woman is the
chief executive is negative and significant at the
1% level. The variable that captures that a
woman chairs the organization is also negative
and significant, but only at the 10% level.
Therefore having a woman in any of these two
preeminent positions results in lower clinical
negligence costs, and the chief executive
position, as expected, is the most influential.
Interpretation and implications
By comparison with FTSE firms in the Davies
Table 3. Characteristics of NHS foundation trusts.
Mean Standard deviation
Assets (£000) SIZE 167,379 134,489
Leverage 0.15 0.23
Proportion not a mental health FT NOMENTAL 0.75 0.44
Board size (number of directors) BDSIZE 13.23 1.73
Board independence (NED/total directors) 0.48 0.06
Proportion of female executive directors FED 0.4 0.2
Proportion of female non executive directors FNED 0.32 0.16
Proportion with female chair FCH 0.28 0.48
Proportion with female chief executive FCE 0.36 0.48
Return on assets 0.03 0.08
Clinical negligence (£000) 2,615 2,234
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Review: female presence on the boards of
directors in the NHS is higher; more
concentrated in executive roles; and more likely
to include a woman in the top positions (chief
executive and chair).
Research on how these boards, where
there is greater female presence, perform
can therefore inform expectations and policy
development for more gender diversity
across all sectors: public, charity and business
sector. The research is particularly relevant
to the scope of the 2016/17 inquiry of the
Women and Equalities Committee as it
considers not just the level of diversity, but
also the effect of women in the most senior
board positions (chief executive officer and
chair). In October 2015, only five FTSE 100
companies had a female CEO (Davies
Review). Currently, there are moves to
increase the number of women on boards,
but the relative board position has not been
fully considered. The study of women on the
boards of NHS FTs informs the debate:
•A high female presence among executive and
non-executive directorships does not result
in significant differences either in financial
goals or service quality among the FTs
studied. However, other studies in other
sectors have found that having a critical
mass of women is important for a
performance effect (Torchia et al., 2011). In
FTs, arguably not only has a critical mass
been reached, but gender diversity has
reached a level where further ‘gender
diversity’ (a higher proportion of female
directors), may not achieve an additional
measurable influence on performance. These
results show no further effect on performance
of greater female representation, but there
are strong representational and opportunity
reasons for requiring more women on
boards.
•Women in prominent board positions (chairs
and particularly chief executives) do exert a
positive influence on service quality in FTs.
Women in the higher echelon appear to be
effective in helping boards meet the
organization’s service quality goals. There is
no adverse effect on financial performance.
Manner (2010) also showed that having a
female chief executive is positively and
significantly related to the level of corporate
social performance engaged in by the firm.
However, Manner warned about drawing
conclusions from this finding because of the
very small proportion of female chief
executives (3%) in his sample.
The research study in FTs in England,
where women are well represented on boards
and where a woman frequently occupies one of
the two most influential positions (chair and
chief executive), has implications for gender
targets on the boards of directors in business
and other sectors. To monitor improvement in
gender equality in the executive layer, the
measures of female presence on the board
should include:
•Number and percentage of female executive
directors.




The research in FTs indicates that, for gender
diversity to be most effective, women need to
be in executive positions at the top level.
However, although there is little doubt
that women will influence firm and public
sector organizational outcomes, we need a better
understanding of what women bring to the
boardroom table and how gender diversity
affects outcomes. Economies do better when
the full talent pool is accessed and women are
able to reach their potential, but there is much
to learn about the constraints women face and
career progression from investigating female
board representation. More research is needed.
Nevertheless, our research indicates the
government should aim to ensure women
are able to reach the most prominent
positions on boards (not merely achieve
appropriate female presence). Once a critical
mass of women is reached, there is little
effect of women across board performance
in the NHS in England. However, there are
strong representational and opportunity
reasons for requiring more women on boards.
Furthermore, companies are now required
to meet social targets (for example
environmental), as well as deliver against
their own financial goals. In order to achieve
Table 4. Results of the multivariate analysis.
Return on assets Clinical negligence costs
Std beta Sig. Std beta Sig.
Female ED 0.027 0.624 0.018 0.624
FNED 0.049 0.340 -0.021 0.538
FCH -0.001 0.987 -0.065* 0.064
FCE -0.032 0.566 0.098** 0.007
R2 = 0.241; N =316; R2 = 0.675; N = 316;
F = 8.782** F = 57.359**
*Significant at 0.1; **significant at 0.01.
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this, companies would benefit from higher
numbers of women in the most senior
positions: chair and, in particular, chief
executive. Consideration should be given to
introducing mechanisms that ensure more
women are able to reach the most senior
positions in both private sector and public
sector organizations.
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IMPACT
The study of female presence on the boards of NHS foundation trusts has important
implications for gender targets in the public sector and the business sector. Women have
impact when in top positions: the chair and, most influentially, the chief executive.
